AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24045520 — intervention group
Group type: COMPARATOR
Intervention: Timolol plus latanoprost (fixed combination therapy)
Number of subjects: 30
Study 20604697 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting CARE suicide prevention program
Number of subjects: 593
Study 18156457 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-reduced group (50% reduced standard doses of nonfractionated heparin)
Number of subjects: 170
Study 18156457 — intervention group
Group type: COMPARATOR
Intervention: Control group (full dose of heparin)
Number of subjects: 170
Study 18156457 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-reduced group
Number of subjects: 170
Study 18156457 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 18156457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study 16177595 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal steady-state exercise (cycle ergometry at 40% of peak oxygen capacity) for 25 minutes
Number of subjects: 65
Study 16177595 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 65
Study 16177595 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (without comorbid FM)
Number of subjects: 65
Study 16177595 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS + FM patients
Number of subjects: 65
Study 16177595 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (pre- and postexercise)
Number of subjects: 65
Study 12860546 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft reconstruction
Number of subjects: 65
Study 12860546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft reconstruction
Number of subjects: 65
Study 12860546 — intervention group
Group type: COMPARATOR
Intervention: Both grafts
Number of subjects: 65
Study 11036880 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram 1-thyroxine daily (Thyroxine group)
Number of subjects: 60
Study 11036880 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control group)
Number of subjects: 60
Study 8899359 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized behavioral feeding intervention
Number of subjects: 88
Study 8899359 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study 1794835 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg afloqualone
Number of subjects: 12
Study 1794835 — intervention group
Group type: COMPARATOR
Intervention: 15 mg diazepam
Number of subjects: 12
Study 1794835 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g/kg ethanol
Number of subjects: 12
Study 6305185 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 (low-fiber diet with spinach every other day)
Number of subjects: 12
Study 6305185 — intervention group
Group type: COMPARATOR
Intervention: Diet 2 (fiber in fruits and vegetables including spinach every other day)
Number of subjects: 12
Study 6305185 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 3 (same as Diet 2 but with cauliflower instead of spinach)
Number of subjects: 12
Study 30586008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (VitE)
Number of subjects: 228
Study 30586008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 30285459 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus tendon graft with intact tibial insertion
Number of subjects: 64
Study 30285459 — intervention group
Group type: COMPARATOR
Intervention: Control group with free semitendinosus tendons
Number of subjects: 64
Study 26749289 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 751
Study 26749289 — intervention group
Group type: COMPARATOR
Intervention: Lantus insulin glargine (IGlar)
Number of subjects: 751
Study 25027157 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture penetrating the skin
Number of subjects: 400
Study 25027157 — intervention group
Group type: COMPARATOR
Intervention: Skin-touch placebo
Number of subjects: 400
Study 25027157 — intervention group
Group type: COMPARATOR
Intervention: No-touch placebo needles
Number of subjects: 400
Study 25027157 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 400
Study 23114140 — intervention group
Group type: EXPERIMENTAL
Intervention: hiDLI plus IL‐2
Number of subjects: 49
Study 23114140 — intervention group
Group type: COMPARATOR
Intervention: mix‐HSCT only
Number of subjects: 49
Study 19344229 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (COL) 3.75 grams/day
Number of subjects: 1018
Study 19344229 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (COL)
Number of subjects: 1018
Study 17570999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of frequency doubling technology (FDT) perimetry and short-wavelength perimetry (SWAP)
Number of subjects: 109
Study 17570999 — intervention group
Group type: COMPARATOR
Intervention: Short-wavelength perimetry (SWAP)
Number of subjects: 109
Study 17570999 — intervention group
Group type: COMPARATOR
Intervention: Frequency doubling technology (FDT) perimetry
Number of subjects: 109
Study 17570999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FDT and SWAP
Number of subjects: 109
Study 14980754 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture
Number of subjects: 192
Study 14980754 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized acupuncture
Number of subjects: 192
Study 14980754 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (invasive sham)
Number of subjects: 192
Study 14980754 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (individualized, standardized, control)
Number of subjects: 192
Study 12167181 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g daily MgSO(4) infusion applied the day before surgery, just after operation, and 4 days following surgery
Number of subjects: 148
Study 12167181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium treatment)
Number of subjects: 148
Study 12167181 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g daily MgSO(4) infusion
Number of subjects: 148
Study 9649905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency QRS components during balloon inflation
Number of subjects: 19
Study 9649905 — intervention group
Group type: COMPARATOR
Intervention: Standard 12-lead ECG ST-segment deviations
Number of subjects: 19
Study 8583478 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 0
Study 8583478 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 0
Study 8583478 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily
Number of subjects: 0
Study 8583478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2655682 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CBZ-CR)
Number of subjects: 8
Study 2655682 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbamazepine (CBZ-C)
Number of subjects: 8
Study 2655682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (CBZ-C and CBZ-CR)
Number of subjects: 8
Study 792985 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐Nle‐M (0.4 mug/kg‐h)
Number of subjects: 6
Study 792985 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 6
Study 30782893 — intervention group
Group type: EXPERIMENTAL
Intervention: HORYZONS plus treatment as usual (TAU)
Number of subjects: 170
Study 30782893 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 170
Study 30782893 — intervention group
Group type: EXPERIMENTAL
Intervention: HORYZONS plus TAU
Number of subjects: 170
Study 28418763 — intervention group
Group type: COMPARATOR
Intervention: Combined‐modality treatment in HD7 (N = 627; median follow‐up, 120 months)
Number of subjects: 4276
Study 28418763 — intervention group
Group type: COMPARATOR
Intervention: Two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved‐field (IF)‐RT in HD10 (N = 1,190; median follow‐up, 98 months)
Number of subjects: 4276
Study 28418763 — intervention group
Group type: COMPARATOR
Intervention: Involved‐field RT in HD8 (N = 1,064; median follow‐up, 153 months)
Number of subjects: 4276
Study 28418763 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at baseline in HD11 (N = 1,395; median follow‐up, 106 months)
Number of subjects: 4276
Study 28418763 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD-treated patients receiving 20 Gy instead of 30 Gy IF‐RT in HD11
Number of subjects: 4276
Study 25219291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 190306
Study 25219291 — intervention group
Group type: COMPARATOR
Intervention: Current reference treatments
Number of subjects: 190306
Study 23992914 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening instrument before and at the end of radiation treatment
Number of subjects: 568
Study 23992914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening instrument)
Number of subjects: 568
Study 21306277 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal surgery
Number of subjects: 158
Study 21306277 — intervention group
Group type: COMPARATOR
Intervention: Postnatal surgery
Number of subjects: 158
Study 19758710 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopic powered adenoidectomy (TEPA)
Number of subjects: 40
Study 19758710 — intervention group
Group type: COMPARATOR
Intervention: Curettage adenoidectomy (CA)
Number of subjects: 40
Study 17305759 — intervention group
Group type: EXPERIMENTAL
Intervention: True eradication therapy
Number of subjects: 184
Study 15242467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg/d)
Number of subjects: 784
Study 15242467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study 11302355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory focusing
Number of subjects: 42
Study 11302355 — intervention group
Group type: COMPARATOR
Intervention: Music distraction
Number of subjects: 42
Study 11302355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 9018647 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (single agent)
Number of subjects: 40
Study 9018647 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate + Misoprostol (control)
Number of subjects: 40
Study 7876405 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg orlistat three times a day at mid-meal (group A)
Number of subjects: 16
Study 7876405 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg orlistat at mid-meal and 0.5, 1, and 2 hr after mid-meal (group B)
Number of subjects: 16
Study 7876405 — intervention group
Group type: COMPARATOR
Intervention: Placebo at mid-meal and 0.5, 1, and 2 hr after mid-meal (group A)
Number of subjects: 16
Study 7876405 — intervention group
Group type: COMPARATOR
Intervention: Placebo at mid-meal (group B)
Number of subjects: 16
Study 3422693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1-g single dose)
Number of subjects: 99
Study 3422693 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2-g each)
Number of subjects: 99
Study 3422693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 99
Study 3422693 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 99
Study 3422693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime and Cefoxitin
Number of subjects: 99
Study 31676260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks (∼15 min HIIT + 30 min sport activities, 3 times/week)
Number of subjects: 38
Study 31676260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 38
Study 30734406 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT-BN)
Number of subjects: 110
Study 30734406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT-A)
Number of subjects: 110
Study 30734406 — intervention group
Group type: COMPARATOR
Intervention: Both FBT-BN and CBT-A
Number of subjects: 110
Study 27443596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Number of subjects: 600
Study 27443596 — intervention group
Group type: COMPARATOR
Intervention: 6-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Number of subjects: 600
Study 25458830 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-sufficient, carbohydrate-free diet
Number of subjects: 7
Study 25458830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 7
Study 25458830 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 7
Study 23326612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass antibiotic distribution (specifics not provided)
Number of subjects: 48
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (3 mg/kg of weight, n=40)
Number of subjects: 160
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (30 mg/kg weight, n=40)
Number of subjects: 160
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (8.5 mg/kg of weight, n=40)
Number of subjects: 160
Study 21911317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=40)
Number of subjects: 160
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 160
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 160
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 160
Study 21911317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21911317 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 160
Study 18243375 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-education intervention
Number of subjects: 827
Study 18243375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 827
Study 16813627 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (EA) - first walk postoperative day 1 or 2
Number of subjects: 60
Study 16813627 — intervention group
Group type: COMPARATOR
Intervention: Delayed ambulation (DA) - first walk postoperative day 3 or 4
Number of subjects: 60
Study 15727424 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (150 mg daily starting 1 day after surgery)
Number of subjects: 18
Study 15727424 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment without chloroquine)
Number of subjects: 18
Study 15727424 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 18
Study 11086771 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of ampicillin/sulbactam (Group 1)
Number of subjects: 317
Study 11086771 — intervention group
Group type: COMPARATOR
Intervention: 24 hours of ampicillin/sulbactam followed by 4 days of placebo (Group 2)
Number of subjects: 317
Study 8817406 — intervention group
Group type: COMPARATOR
Intervention: Salt-restriction placebo
Number of subjects: 39
Study 8817406 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-restriction cilazapril (2.5 mg daily)
Number of subjects: 39
Study 1579872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal chymopapain
Number of subjects: 60
Study 1579872 — intervention group
Group type: COMPARATOR
Intervention: Intradiscal normal saline
Number of subjects: 60
Study 3907278 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine decanoate (PD) 100 mg intramuscularly every two weeks
Number of subjects: 50
Study 3907278 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine enanthate (PE) 100 mg intramuscularly every two weeks
Number of subjects: 50
Study 3907278 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine enanthate (PE)
Number of subjects: 50
Study 3907278 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine decanoate (PD)
Number of subjects: 50
Study 31440874 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 164
Study 31440874 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 164
Study 31440874 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact intervention
Number of subjects: 164
Study 31440874 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 164
Study 29720733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib added to intensive induction and consolidation chemotherapy and administered as a single agent for 1-year maintenance.
Number of subjects: 89
Study 29720733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib treatment
Number of subjects: 89
Study 27936206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N = 59)
Number of subjects: 80
Study 27936206 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 21)
Number of subjects: 80
Study 24762958 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly targeted therapy based on tumour molecular profiling
Number of subjects: 100
Study 24762958 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 100
Study 23165659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil plus testosterone (10-g transdermal gel for 14 weeks)
Number of subjects: 140
Study 23165659 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil plus placebo
Number of subjects: 140
Study 20517210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexin (10 mg/d intramuscular for 10 days) along with standard therapy
Number of subjects: 30
Study 20517210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cortexin)
Number of subjects: 30
Study 17562666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 160
Study 17562666 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 160
Study 15847730 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 459
Study 11807700 — intervention group
Group type: EXPERIMENTAL
Intervention: Home sampling kit mailed directly to home address (n=4500)
Number of subjects: 30439
Study 11807700 — intervention group
Group type: EXPERIMENTAL
Intervention: Reply card mailed to home address with option to order home sampling kit (n=4500)
Number of subjects: 30439
Study 11807700 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=21,439)
Number of subjects: 30439
Study 10360853 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 20 mg (P-20)
Number of subjects: 69
Study 10360853 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 40 mg (P-40)
Number of subjects: 69
Study 10360853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intralipid)
Number of subjects: 69
Study 8530603 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 36
Study 8530603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2200257 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol OROS (14/190 mg)
Number of subjects: 12
Study 2200257 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 6271426 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-prepared patients
Number of subjects: 20
Study 28237177 — intervention group
Group type: EXPERIMENTAL
Intervention: EFJ group
Number of subjects: 322
Study 28237177 — intervention group
Group type: COMPARATOR
Intervention: non-EFJ group
Number of subjects: 322
Study 29457191 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 46
Study 29457191 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 46
Study 27212228 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 100
Study 27212228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27212228 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3
Number of subjects: 100
Study 24366930 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (alloSCT)
Number of subjects: 370
Study 24366930 — intervention group
Group type: COMPARATOR
Intervention: Conventional postremission therapy
Number of subjects: 370
Study 22389708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polyethylene glycol‐based bowel cleansing preparation
Number of subjects: 12
Study 22389708 — intervention group
Group type: COMPARATOR
Intervention: Un‐prepped flexible sigmoidoscopy
Number of subjects: 12
Study 22389708 — intervention group
Group type: COMPARATOR
Intervention: 24‐hour clear liquid diet followed by un‐prepped flexible sigmoidoscopy
Number of subjects: 12
Study 19755327 — intervention group
Group type: EXPERIMENTAL
Intervention: GuardWire distal protection
Number of subjects: 501
Study 17974864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 487
Study 17974864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg/day
Number of subjects: 487
Study 17974864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg/day
Number of subjects: 487
Study 17974864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 15734296 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral treatment (200 ml water + 100 mg danazol capsule + 3 x 500 mg paracetamol tablets + 2 x 500 mg sulfasalazine tablets)
Number of subjects: 8
Study 15734296 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard + lipid-rich meal treatment
Number of subjects: 8
Study 15734296 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 8
Study 15734296 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard + 800 ml water treatment
Number of subjects: 8
Study 11788220 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of phosphorothioate-modified 15-mer antisense ODN
Number of subjects: 85